Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2015 Apr;16 Suppl 1(0 1):1-9.
doi: 10.1111/hiv.12227.

Why START? Reflections that led to the conduct of this large long-term strategic HIV trial

INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group; Jens Lundgren, Abdel Babiker, Fred Gordin, Sean Emery, Gerd Fätkenheuer, Jean-Michel Molina, Robin Wood, James D Neaton
Collaborators
Editorial

Why START? Reflections that led to the conduct of this large long-term strategic HIV trial

INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group et al. HIV Med. 2015 Apr.
No abstract available

Keywords: CD4-guided ART; HIV; START trial; antiretroviral therapy; when to start.

PubMed Disclaimer

Figures

Figure 1
Figure 1. The design of the START trial
Legend: ART-naïve (i.e, persons not previously using antiretroviral therapy [ART]) HIV-positive persons with normal immune function (i.e., a CD4 cell count above 500 cells/μL) are randomly allocated to start ART immediately or until the CD4 count has further decreased to levels below which the person starts to become at risk of contracting opportunistic diseases (i.e., AIDS) if left untreated; if AIDS develops when the CD4 count is still above 350 cells/μL then ART should also be initiated.
See this image and copyright information in PMC

References

    1. Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis. 2008;197:1133–1144. - PubMed
    1. Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med. 2010;363:257–265. - PMC - PubMed
    1. Grinsztejn B, Hosseinipour MC, Ribaudo HJ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014;14:281–290. - PMC - PubMed
    1. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360:1815–1826. - PMC - PubMed
    1. Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373:1352–1363. - PMC - PubMed

Publication types

Substances

Associated data